53. Li L, Yang J, Peng D, Zhang Y, Chen Y.177Lu-FAP-2286 therapy in a case of recurrent bladder cancer with multiple metastatic lesions. Clin Nucl Med. 2023;48:1012–1014. 54. Rao Z, Zhang Y, Liu L, Wang M...
We report a 38-year-old man with radio-iodine refractory papillary thyroid carcinoma (RAIR PTC) who experienced significant relief from symptoms and showed a positive biochemical response after undergoing a single cycle of177Lu-FAPI-2286 therapy. A pretreatment99mTc-FAPI-46 scan showed diffuse ...
尽管FAPI PET在肿瘤预后判断中的相关研究样本数量较少、随访时间较短,随着病例的积累和对核素显像定量、半定量指标与临床资料进行详细解析,相信可以得到更多对临床有价值的信息。 FAP在多种癌症基质组织中过度表达,且经显像证实具有高肿瘤摄取、低本底摄取的特征,是...
FAP在多种癌症基质组织中过度表达,且经显像证实具有高肿瘤摄取、低本底摄取的特征,是放射性配体治疗(targeted radioligand therapy, TRT)的优越靶点。已有多项临床前研究和临床系列病例报道应用靶向FAP的抗体、肽类和小分子化合物进行TRT的初步探索。但是目前研究面临的一个重要问题是,这些FAPI分子存在快速被清除和在肿瘤...
FAP在多种癌症基质组织中过度表达,且经显像证实具有高肿瘤摄取、低本底摄取的特征,是放射性配体治疗(targeted radioligand therapy, TRT)的优越靶点。已有多项临床前研究和临床系列病例报道应用靶向FAP的抗体、肽类和小分子化合物进行TRT的初步探索。但是目前研究面临的一个重要问题是,这些FAPI分子存在快速被清除和在肿瘤...
Baum RP, Schuchardt C, Singh A, et al. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: first-in-Humans Results.J Nucl Med. 2022;63(3):415–423. DOI:10.2967/jnumed.120.259192 ...
Banihashemian SS, Bayat M, Pirayesh E, Divband G, Abolhosseini A, Akbari ME (2024) First experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma. Clin Nucl Med 49:e334–e337. https://doi.org/10.1097/RLU.0000000000005255 Article PubMed Googl...
Bridge Institute of Experimental Tumor Therapy, West German Cancer Center, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany Jens T. Siveke Division of Solid Tumor Translational Oncology, German Cancer Center Consortium (DKTK Partner Site Essen), and German Cancer Research Center, ...
FAP在多种癌症基质组织中过度表达,且经显像证实具有高肿瘤摄取、低本底摄取的特征,是放射性配体治疗(targeted radioligand therapy, TRT)的优越靶点。已有多项临床前研究和临床系列病例报道应用靶向FAP的抗体、肽类和小分子化合物进行TRT的初步探索。但是目前研究面临的一个重要问题是,这些FAPI分子存在快速被清除和在肿瘤...
53. Li L, Yang J, Peng D, Zhang Y, Chen Y.177Lu-FAP-2286 therapy in a case of recurrent bladder cancer with multiple metastatic lesions. Clin Nucl Med. 2023;48:1012–1014. 54. Rao Z, Zhang Y, Liu L, Wang M...